Word

UBRELVY

Status

Registered

Status Code

700

Status Date

Tuesday, June 9, 2020

Serial Number

88185227

Registration Number

6075800

Registration Date

Tuesday, June 9, 2020

Mark Type

3000

Filing Date

Wednesday, November 7, 2018

Published for Opposition

Tuesday, March 5, 2019

Trademark Owner History

Allergan Pharmaceuticals International Limited - Original Registrant

Classifications

5 Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Color is not claimed as a feature of the mark.
The mark consists of the word "UBRELVY" below two wavy lines, both of which generally begin above the "E" in "UBRELVY" and extend in opposite directions.

Trademark Events

Jun 9, 2020

Registered-Principal Register

May 2, 2020

Notice Of Acceptance Of Statement Of Use E-Mailed

May 1, 2020

Allowed Principal Register - Sou Accepted

Apr 20, 2020

Statement Of Use Processing Complete

Apr 6, 2020

Use Amendment Filed

Apr 20, 2020

Case Assigned To Intent To Use Paralegal

Apr 6, 2020

Teas Statement Of Use Received

Oct 30, 2019

Notice Of Approval Of Extension Request E-Mailed

Oct 28, 2019

Extension 1 Granted

Oct 28, 2019

Extension 1 Filed

Oct 28, 2019

Teas Extension Received

Apr 30, 2019

Noa E-Mailed - Sou Required From Applicant

Mar 5, 2019

Official Gazette Publication Confirmation E-Mailed

Mar 5, 2019

Published For Opposition

Feb 13, 2019

Notification Of Notice Of Publication E-Mailed

Jan 25, 2019

Approved For Pub - Principal Register

Jan 24, 2019

Assigned To Examiner

Nov 27, 2018

Notice Of Design Search Code E-Mailed

Nov 24, 2018

New Application Office Supplied Data Entered In Tram

Nov 10, 2018

New Application Entered In Tram